Short Interest in ASP Isotopes Inc. (NASDAQ:ASPI) Decreases By 7.8%

ASP Isotopes Inc. (NASDAQ:ASPI) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 5,950,000 shares, a drop of 7.8% from the November 30th total of 6,450,000 shares. Based on an average daily trading volume, of 4,970,000 shares, the short-interest ratio is presently 1.2 days. Approximately 12.8% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Canaccord Genuity Group started coverage on ASP Isotopes in a report on Friday, October 4th. They set a “buy” rating and a $4.50 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $4.50 price objective on shares of ASP Isotopes in a research report on Friday, October 18th.

ASP Isotopes Stock Down 1.1 %

Shares of ASPI stock traded down $0.05 on Wednesday, reaching $4.53. 1,943,606 shares of the stock were exchanged, compared to its average volume of 1,900,932. ASP Isotopes has a twelve month low of $1.65 and a twelve month high of $9.33. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $323.40 million, a price-to-earnings ratio of -7.43 and a beta of 3.27. The business’s 50 day moving average price is $5.93 and its 200 day moving average price is $3.94.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in ASP Isotopes by 31.4% during the third quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock worth $62,000 after purchasing an additional 5,307 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in ASP Isotopes during the third quarter worth approximately $42,000. Sanctuary Advisors LLC purchased a new stake in shares of ASP Isotopes during the 3rd quarter worth approximately $66,000. Barclays PLC boosted its holdings in shares of ASP Isotopes by 438.5% in the 3rd quarter. Barclays PLC now owns 72,330 shares of the company’s stock valued at $201,000 after buying an additional 58,897 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of ASP Isotopes by 42.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,118,423 shares of the company’s stock valued at $3,110,000 after buying an additional 334,836 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.